CCA
CRMD icon

Catalyst Capital Advisors’s CorMedix CRMD Stock Holding History

Catalyst Capital Advisors’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-40,800
Closed -$386K – 429
2019
Q1 		$386K Buy
+40,800
New +$368K 0.01% 186

Other funds holding CRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
SC
Spinnaker Capital Boston, Massachusetts $1.08M AUM 45.28% 1-Year Est. Return

Catalyst Capital Advisors's CRMD Position: Q2 2019 in Review

Catalyst Capital Advisors sold out of CorMedix (CRMD) in Q2 2019, closing a stake of 40,800 shares — an estimated $386K sold.

Catalyst Capital Advisors first reported a position in CRMD in Q1 2019 and held it in 1 quarter. The position peaked at $386K in Q1 2019. 47 funds tracked by Wall St. Rank hold CRMD as of Q2 2019.

  • Catalyst Capital Advisors reported no remaining CorMedix position as of Q2 2019 after selling out during the quarter.
  • Catalyst Capital Advisors sold 40,800 CorMedix shares in Q2 2019, an estimated $386K.
  • Catalyst Capital Advisors first reported a position in CorMedix in Q1 2019 and held it in 1 quarter.
  • Catalyst Capital Advisors's CorMedix position peaked at $386K in Q1 2019.
  • 47 funds tracked by Wall St. Rank held CorMedix as of Q2 2019.

Based on Catalyst Capital Advisors's 13F filing for Q2 2019, filed 8 Aug 2019.